A Canadian Paediatric Society practice point document addresses the use and interpretation of pharmacogenetic testing for psychoactive medications in children.
Many worry, rightly, that they’ll regain weight and revert to old habits. In clinical trials, patients who paused the drugs put back on most of the weight they lost.
The new drug Litfulo (ritlecitinib) has reached the Canadian market, while baricitinib (Olumiant) is now approved for alopecia areata and in a new higher-strength tablet.
This new combo product will be used to manage heavy menstrual bleeding associated with uterine fibroids, and moderate to severe pain associated with endometriosis.
